The global molecular diagnostic market size surpassed USD 353 million in 2024 and is predicted to reach around USD 542.97 million by 2034, registering a CAGR of 4.4% from 2024 to 2034.
A molecular diagnostic is defined as a test that is conducted to identify a particular sequence in a sample of genomic DNA or RNA to diagnose diseases. Besides, it seeks to determine single nucleotide polymorphism, deletion, rearrangement, and insertion in the DNA sequences. Further, it is important to mention that molecular diagnostics itself is a part of the in vitro diagnostics market. Molecular diagnostic tests are useful in diagnosing diseases, measuring health care, and even determining the responses and outcomes.
Trends including the development of new technologies, higher population records of geriatric people, and a rise in the necessity for precise and efficient genetic tests are the driving forces for this molecular diagnostics market. Also, expanding demand for point-of-care testing can be attributed to a rise in demand for self-testing diagnostics, and higher patient awareness of using faster diagnostics, which is fueling industry players coming up with unique testing products.
Increased health care expenditure coupled with increased attention to preventive health care mandatory in the molecular diagnostics market in the US. The adoption of next-generation sequencing (NGS) technology is increasing rapidly, it is boosting therapeutic options and diagnosing the disease in the United States.
Published by Ajit Bansod
